Medical management of sudden hearing loss.
A hurdle in the evaluation of any therapy of ISHL has previously been proposed-a spontaneous recovery of satisfactory hearing of 63% of patients. The hurdle has yet to be convincingly passed by any drug therapy. The intent here is not to denigrate the use of drugs in this syndrome; on the contrary, it remains likely that some subgroups of ISHL would benefit from specific medical management. For instance, a systemic viremia would be most logically treated with anti-inflammatory agents and a thrombotic event with anticoagulants. However, prospective studies in which patients are divided into prognostic categories before treatment with adequate control groups must be performed.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D003974:Diatrizoate Meglumine / Q000627:therapeutic use; D005728:Ganglia, Sympathetic; D003639:Hearing Loss, Sudden / Q000188:drug therapy*; D006493:Heparin / Q000627:therapeutic use; D006632:Histamine / Q000627:therapeutic use; D006801:Humans; D009407:Nerve Block; D014665:Vasodilator Agents / Q000627:therapeutic use
D000305:Adrenal Cortex Hormones; D000925:Anticoagulants; D014665:Vasodilator Agents; D003974:Diatrizoate Meglumine; D006632:Histamine; D006493:Heparin